title: Early antithrombotic treatment with warfarin oral suspension in severe neonatal protein C deficiency.
abstract: Neonatal severe protein C deficiency is a serious disease. There is no uniform approach for long-term preventive treatment of thrombotic events. We report the case of neonatal severe protein C deficiency treated with warfarin oral suspension. An international normalized ratio (INR) from 2.5 to 3.5 was expected. The INR was measured by home monitoring using the Coaguchek XS®(Roche Diagnostics, Mannheim, Germany) monitor. During 2years of warfarin treatment, there were only two minor episodes of purpuric access and no bleeding was reported. This case suggests that the early introduction of warfarin oral suspension, home-care monitoring, and parental education programs may be a beneficial treatment option for children with protein C deficiency.
authors.affiliation: Department of Neonatology, Grenoble Alpes University Hospital, CS10217, 38043 Grenoble cedex 9, France. Electronic address: cmilleret1@chu-grenoble.fr.
authors.forename: C
authors.initials: C
authors.lastname: Milleret
authors.affiliation: Department of Neonatology, Grenoble Alpes University Hospital, CS10217, 38043 Grenoble cedex 9, France.
authors.forename: C
authors.initials: C
authors.lastname: Epiard
authors.affiliation: Department of Pediatrics, Grenoble Alpes University Hospital, CS10217, 38043 Grenoble cedex 9, France.
authors.forename: S
authors.initials: S
authors.lastname: Douchin
authors.affiliation: Department of Vascular Medicine, Grenoble Alpes University Hospital, CS10217, 38043 Grenoble cedex 9, France.
authors.forename: G
authors.initials: G
authors.lastname: Pernod
authors.affiliation: Department of Neonatology, Grenoble Alpes University Hospital, CS10217, 38043 Grenoble cedex 9, France.
authors.forename: T
authors.initials: T
authors.lastname: Debillon
mesh_terms: D000284:Administration, Oral; D002405:Catheterization, Central Venous; D002675:Child, Preschool; D003241:Consanguinity; D042241:Early Diagnosis; D061345:Early Medical Intervention; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D018575:Home Care Services, Hospital-Based; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019934:International Normalized Ratio; D011486:Protein C / Q000008:administration & dosage; D020151:Protein C Deficiency / Q000188:drug therapy* / Q000235:genetics; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D011486:Protein C; D014859:Warfarin